Skip to main content

Table 5 Clinical characteristics during the follow-up period

From: Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records

Characteristic

Confirmed HAE

(n = 254)

Suspected HAE

(n = 1299)

Duration of follow-up period (months)

  

 Mean (SD)

50.0 (34.3)

45.9 (33.1)

 Median (IQR)

45.7 (19.4–72.0)

37.8 (16.9–70.5)

Number of visits during the follow-up period

 

 Mean (SD)

1.14 (1.10)

1.02 (0.91)

 Median (IQR)

0.77 (0.40–1.48)

0.75 (0.34–1.46)

Prescriptions for HAE-specific medication

 Patients with ≥ 1 prescription, n (%)

79 (31.1)

30 (2.3)

 Prescriptions PPPM

  

  Mean (SD)

0.18 (0.18)

0.13 (0.23)

  Median (IQR)

0.10 (0.05–0.29)

0.07 (0.03–0.11)

 Type of treatment, n (%)

  

  C1 inhibitor

45 (17.7)

5 (0.4)

  Ecallantide

11 (4.3)

3 (0.2)

  Icatibant

26 (10.2)

4 (0.3)

  Androgen

35 (13.8)

22 (1.7)

HAE attack diagnosis and/or procedure codes

 Patients with evidence of ≥ 1 HAE attack, n (%)

106 (41.7)

389 (29.9)

 HAE attacks PPPM

  

  Mean (SD)

0.05 (0.09)

0.03 (0.07)

  Median (IQR)

0.02 (0.00–0.06)

0.00 (0.00–0.03)

  1. HAE hereditary angioedema, IQR interquartile range, PPPM per patient per month, SD standard deviation